BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32590342)

  • 21. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.
    Shattuck TM; Välimäki S; Obara T; Gaz RD; Clark OH; Shoback D; Wierman ME; Tojo K; Robbins CM; Carpten JD; Farnebo LO; Larsson C; Arnold A
    N Engl J Med; 2003 Oct; 349(18):1722-9. PubMed ID: 14585940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
    Hahn MA; Howell VM; Gill AJ; Clarkson A; Weaire-Buchanan G; Robinson BG; Delbridge L; Gimm O; Schmitt WD; Teh BT; Marsh DJ
    Endocr Relat Cancer; 2010 Mar; 17(1):273-82. PubMed ID: 20026646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
    Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
    Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Large intragenic deletion of CDC73 (exons 4-10) in a three-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family.
    Guarnieri V; Seaberg RM; Kelly C; Jean Davidson M; Raphael S; Shuen AY; Baorda F; Palumbo O; Scillitani A; Hendy GN; Cole DEC
    BMC Med Genet; 2017 Aug; 18(1):83. PubMed ID: 28774260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation.
    Kelly TG; Shattuck TM; Reyes-Mugica M; Stewart AF; Simonds WF; Udelsman R; Arnold A; Carpenter TO
    J Bone Miner Res; 2006 Oct; 21(10):1666-71. PubMed ID: 16995822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.
    Sulaiman L; Haglund F; Hashemi J; Obara T; Nordenström J; Larsson C; Juhlin CC
    PLoS One; 2012; 7(9):e46325. PubMed ID: 23029479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding the genetic basis of parathyroid carcinoma.
    Gill AJ
    Endocr Pathol; 2014 Mar; 25(1):30-4. PubMed ID: 24402736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Para This, Fibromin That: The Role of CDC73 in Parathyroid Tumors and Familial Tumor Syndromes.
    Ababneh E; Nosé V
    Surg Pathol Clin; 2023 Mar; 16(1):97-105. PubMed ID: 36739170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours.
    Bradley KJ; Cavaco BM; Bowl MR; Harding B; Cranston T; Fratter C; Besser GM; Conceição Pereira M; Davie MW; Dudley N; Leite V; Sadler GP; Seller A; Thakker RV
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):299-306. PubMed ID: 16487440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A family case report of parathyroid carcinoma associated with
    Gu Y; Ye Y; Shu H; Chang L; Xie Y; Li F; Zhu T; Liu M; He Q
    Front Endocrinol (Lausanne); 2024; 15():1330185. PubMed ID: 38348418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of a new CDC73 missense mutation that impairs Parafibromin expression and nucleolar localization.
    Masi G; Iacobone M; Sinigaglia A; Mantelli B; Pennelli G; Castagliuolo I; Palù G; Barzon L
    PLoS One; 2014; 9(5):e97994. PubMed ID: 24842573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
    Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
    J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.
    Carpten JD; Robbins CM; Villablanca A; Forsberg L; Presciuttini S; Bailey-Wilson J; Simonds WF; Gillanders EM; Kennedy AM; Chen JD; Agarwal SK; Sood R; Jones MP; Moses TY; Haven C; Petillo D; Leotlela PD; Harding B; Cameron D; Pannett AA; Höög A; Heath H; James-Newton LA; Robinson B; Zarbo RJ; Cavaco BM; Wassif W; Perrier ND; Rosen IB; Kristoffersson U; Turnpenny PD; Farnebo LO; Besser GM; Jackson CE; Morreau H; Trent JM; Thakker RV; Marx SJ; Teh BT; Larsson C; Hobbs MR
    Nat Genet; 2002 Dec; 32(4):676-80. PubMed ID: 12434154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The EIF4EBP3 translational repressor is a marker of CDC73 tumor suppressor haploinsufficiency in a parathyroid cancer syndrome.
    Zhang JH; Seigneur EM; Pandey M; Loshakov A; Dagur PK; Connelly PS; Koo L; Panicker LM; Simonds WF
    Cell Death Dis; 2012 Feb; 3(2):266. PubMed ID: 22297294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIGH RISK OF PARATHYROID CARCINOMA AND GENETIC SCREENING IN THE FIRST DIAGNOSED ROMANIAN FAMILY WITH HYPERPARATHYROIDISM-JAW TUMOR SYNDROME AND A GERMLINE MUTATION OF THE CDC73 GENE.
    Grigorie D; Sucaliuc A; Ciuffi S; Franceschelli F; Marini F; Ioachim D; Terzea D; Brandi MLL
    Acta Endocrinol (Buchar); 2019; 15(3):398-403. PubMed ID: 32010362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association Between Parafibromin Expression and Presence of Brown Tumors and Jaw Tumors in Patients with Primary Hyperparathyroidism: Series of Cases with Review of the Literature.
    Popow M; Kaszczewska M; Góralska M; Kaszczewski P; Skwarek-Szewczyk A; Chudziński W; Jażdżewski K; Kolanowska M; Bogdańska M; Starzyńska-Kubicka A; Gałązka Z
    Am J Case Rep; 2022 Oct; 23():e936135. PubMed ID: 36271606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome.
    Mizusawa N; Uchino S; Iwata T; Tsuyuguchi M; Suzuki Y; Mizukoshi T; Yamashita Y; Sakurai A; Suzuki S; Beniko M; Tahara H; Fujisawa M; Kamata N; Fujisawa K; Yashiro T; Nagao D; Golam HM; Sano T; Noguchi S; Yoshimoto K
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):9-16. PubMed ID: 16817812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum.
    Frank-Raue K; Haag C; Schulze E; Keuser R; Raue F; Dralle H; Lorenz K
    Eur J Endocrinol; 2011 Sep; 165(3):477-83. PubMed ID: 21652691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma.
    Korpi-Hyövälti E; Cranston T; Ryhänen E; Arola J; Aittomäki K; Sane T; Thakker RV; Schalin-Jäntti C
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3044-8. PubMed ID: 24823466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rare duplication of the CDC73 gene and atypical hyperparathyroidism-jaw tumor syndrome: A case report and review of the literature.
    Garrigues G; Batisse-Lignier M; Uhrhammer N; Privat M; Ponelle-Chachuat F; Kelly A; Gay-Bellile M; Viala S; Bidet Y; Bignon YJ; Cavaillé M
    Mol Genet Genomic Med; 2023 May; 11(5):e2133. PubMed ID: 36639964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.